Status:
COMPLETED
The Cardio-protective Effect of Cardiomyopeptidin on Myocardial Injury in ICU Patients With Non-organic Heart Disease: a Prospective, Single-blind, Randomized Controlled Pilot Study
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Myocardial Injury
ICU
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study was a single-center, randomized controlled pilot study. To explore the cardioprotective effect of cardiopeptidin on non-heart disease patients with severe cardiac injury by comparing whether...
Eligibility Criteria
Inclusion
- Age ≥18 years old
- The high-sensitive troponin T index was higher than the normal value during ICU hospitalization
- Obtain the informed consent of the subject or legal agent
Exclusion
- Patients who are expected to die within 48 hours of ICU admission
- previous diagnosis of acute coronary syndrome, chronic cardiomyopathy, pulmonary heart disease, acute myocarditis, pericardial tamponade and other diseases that have been confirmed to cause myocardial injury
- cardiopulmonary resuscitation and/or electrical defibrillation before admission
- patients with acute ischemic stroke
- patients with stage 5 chronic kidney disease
- during pregnancy or breastfeeding
Key Trial Info
Start Date :
February 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 25 2023
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT06117046
Start Date
February 27 2023
End Date
November 25 2023
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern medical university Nanfang hospital
Guangzhou, China, 510515